Scancell Holdings plc (AIM:SCLP)

London flag London · Delayed Price · Currency is GBP · Price in GBX
10.00
+0.25 (2.56%)
Jul 28, 2025, 11:00 AM GMT+1
2.56%
Market Cap101.18M
Revenue (ttm)n/a
Net Income (ttm)-15.81M
Shares Out1.04B
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume365,555
Average Volume932,356
Open9.82
Previous Close9.75
Day's Range9.50 - 10.00
52-Week Range7.26 - 19.75
Beta-0.02
RSI43.03
Earnings DateSep 24, 2025

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 61
Stock Exchange London Stock Exchange AIM
Ticker Symbol SCLP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.